Mangrove Partners Larimar Therapeutics, Inc. Transaction History
Mangrove Partners
- $642 Million
- Q4 2024
A detailed history of Mangrove Partners transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Mangrove Partners holds 770,233 shares of LRMR stock, worth $2.3 Million. This represents 0.46% of its overall portfolio holdings.
Number of Shares
770,233
Previous 855,815
10.0%
Holding current value
$2.3 Million
Previous $5.61 Million
47.51%
% of portfolio
0.46%
Previous 0.73%
Shares
8 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
66.8MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$63.3 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$19.2 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$18 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$13.9 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$12.4 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $129M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...